Post-Interleukin 6

Version vom 18. Juni 2020, 10:37 Uhr

32353761 2020. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review
32247642 ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
32243501 2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
32343968 ä. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
32337664 ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
32359035 2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
32378647 2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
32234467 ä. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
32305588 ä. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
32291137 ä. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
32300051 2020. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
C7154570 2020. Anti-IL6R role in treatment of COVID-19-related ARDS
32290839 2020. Why tocilizumab could be an effective treatment for severe COVID-19?
32372149 ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?